Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds

• ClinicalTrials.gov Identifier: NCT00358774
• Recruitment Status: Completed
• First Posted: August 1, 2006
• Last Update Posted: October 14, 2015
• Sponsor: University of Wisconsin, Madison
• Collaborator: Procter and Gamble
• Information provided by (Responsible Party): University of Wisconsin, Madison

Tracking Information

• First Submitted Date: July 28, 2006
• First Posted Date: August 1, 2006
• Last Update Posted Date: October 14, 2015
• Study Start Date: March 2001
• Actual Primary Completion Date: March 2002 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: July 31, 2006): The proportion of subjects who become infected and show the presence of a cold.(active vs placebo)
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: July 31, 2006)

• The proportion of subjects who become infected.
• The mean number of days that virus was shed for inoculated subjects (active vs placebo)

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds
• Official Title: A Double-blind, Placebo-controlled Trial to Test the Efficacy of Homeopathic Nasal Formulation for the Management of Experimental Rhinoviral Colds in an Outpatient Setting

Brief Summary

Common colds affect many people and are the cause of bothersome symptoms such as runny or stuffy nose, sore throat, headache and sneezing. Common colds can also cause more severe illnesses in certain groups of people like the elderly, people with chronic lung diseases such as asthma.

This study is designed to test whether a non-drug (homeopathic) nasal spray will reduce the incidence of colds, decrease cold related symptoms or shorten the length of the cold.

Detailed Description

Common colds are the most frequent type of respiratory infection, and although the clinical manifestations are usually not life threatening or debilitating, they cause annoying symptoms such as nasal congestion, rhinorrhea, malaise, sore throat and sneezing, that can interfere with activities of daily living. Furthermore, colds can cause more severe illnesses in certain people including: infants, the elderly, and people with asthma, chronic lung diseases, or immune deficiency.

This clinical trial is designed to test whether a new homeopathic formulation has beneficial effects on the management of common colds that have been induced by inoculation of rhinovirus into the nose of healthy subjects.

The objective of this research clinical study is to evaluate the effectiveness of a homeopathic nasal formulation for the management of experimentally-induced common colds as indicated by a reduction in:

• Cold incidence compared to placebo,
• Symptom severity compared to placebo
• Cold duration compared to placebo
• Infection rate compared to placebo
• Duration of virus shedding compared to placebo or
• Amount of virus shedding compared to placebo

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double; Primary Purpose: Prevention
• Condition: Common Cold
• Intervention: Procedure: homeopathic nasal spray
• Study Arms: Not Provided
• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Enrollment (submitted: July 31, 2006): 40
• Original Enrollment: Same as current
• Actual Study Completion Date: March 2002
• Actual Primary Completion Date: March 2002 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

To be considered eligible for enrollment into this study, subject must:

1. Be healthy based on medical history, physical and nasal examination
2. Be male or non-pregnant, non-lactating female (women of child-bearing potential must be using an acceptable form of contraception, including abstinence, as determined by the Investigator)
3. Be between 18 - 60 years old
4. Be willing to refrain from taking nasal decongestants, antihistamines or cough/cold preparations (this includes dietary supplements and homeopathic preparations used specifically for cold/flu e.g., vitamin C, zinc, echinacea) within the 7 days prior to Day 0 and through Day 5
5. Be willing to refrain from taking any other medication (except contraceptive preparations, hormone replacement therapy, acne medication) within 2 days prior to Day 0 and through Day 5
6. Has read, signed and received a copy of the Informed Consent Form.

Exclusion Criteria:

Subjects will be excluded from the study if they:

1. Are intolerant of nasal sprays
2. Require a medication on regular basis (3 or more times/week) except contraceptive preparations, hormone replacement therapy, acne medication
3. Have a history of chronic diseases such as respiratory (e.g., chronic rhinitis, sinusitis, asthma, chronic bronchitis, pneumonia, persistent or chronic cough, emphysema, breathing problems, excessive phlegm or mucus), cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, ophthalmic diseases requiring medication
4. Have a history of headache (e.g., frequent migraines, cluster headaches, 3+ headaches/week)
5. Have had cold symptoms in the past 14 days
6. Are currently symptomatic with respiratory allergy
7. Have any clinically significant abnormalities of the upper (including history of nose bleeds, nasal abnormalities or other nasal pathology such as irreversible nasal mucosal hypertrophy or severe nasal septal deviation) or lower respiratory tract
8. Have used any investigational medication in the past 30 days
9. Are smokers
10. Have serum neutralizing antibody titer of >1 to RV16 at Pre-screening
11. Have a condition or is taking a medication that the Investigator and/or designee believes could jeopardize the safety of the subject, would interfere with the evaluation or confound the interpretation of the study results
12. Have positive urine pregnancy test (for female subjects only)

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 60 Years (Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided

Administrative Information

• NCT Number: NCT00358774
• Other Study ID Numbers: 2001-089
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: University of Wisconsin, Madison
• Study Sponsor: University of Wisconsin, Madison
• Collaborators: Procter and Gamble

Investigators

• Principal Investigator: James E Gern, MD; University of Wisconsin, Madison

• PRS Account: University of Wisconsin, Madison
• Verification Date: October 2015